meta
|
evidence
oncology
Living systematic review and meta-analysis
multiple myeloma - 1st line (L1)
1
All treatments
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab plus lenalidomide and dexamethasone
versus all
vs Immunosuppressant
vs lenalidomide based treatment
vs lenalidomide and dexamethasone
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
summary
GRADE
treatment
patients
risk of bias
overview
numeric
bar chart
forest plot
medians
frequency on treatment
benefit risk analysis
Study
study type
RCT
OBS
RCT + OBS
Pathology
T1
T0
Patients
sample sizes
ROB
Results
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open